drugset / Trial / NCT07471776

Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer

NCT07471776

Phase 2 Recruiting 45 enrolled Fudan University
NaSingle-groupOpen-labelDiagnostic

Summary

This study aims to evaluate whether \^68Ga-TROP2 PET/CT, combined with \^18F-FDG PET/CT, can predict the efficacy of anti-TROP2 antibody-drug conjugates in patients with advanced HER2-negative breast cancer. Baseline and dynamic imaging parameters will be used to develop prediction models (primary endpoint: AUC), and their associations with clinical outcomes and tumor TROP2 status will be explored.

Timeline

Start
2026-03-11
Primary completion
2028-03-11
Completion
2029-03-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Datopotamab deruxtecan Monoclonal antibody
Subject Sacituzumab Govitecan Monoclonal antibody
Subject Sacituzumab Tirumotecan Other / unclassified